Unique ID issued by UMIN | UMIN000047056 |
---|---|
Receipt number | R000053681 |
Scientific Title | J-RECOVER |
Date of disclosure of the study information | 2022/03/02 |
Last modified on | 2022/09/03 07:06:59 |
Japanese multicenter REsearch of COVID-19 by assEmbling Real-world data
J-RECOVER
J-RECOVER
J-RECOVER
Japan |
COVID-19
Infectious disease |
Others
NO
This study aimed to construct a database of confirmed COVID-19 cases in Japan and promptly address unresolved research issues.
Safety
28-day mortality
mortality
Observational
1 | days-old | <= |
120 | years-old | >= |
Male and Female
Patients with COVID-19 who had a laboratory-confirmed SARS-CoV-2 infection were eligible for this study, regardless of being admitted to the ICU.
out of hospital cardiac arrest patient and died at the ED.
4500
1st name | Takashi |
Middle name | |
Last name | Tagami |
Nippon Medical School Musashikosugi Hospital
Department of Emergency and Critical Care Medicine
211-8533
1-396 Kosugimachi, Nakahara-ku, Kawasaki, Kanagawa 211-8533, Japan
0447335181
t-tagami@nms.ac.jp
1st name | Takashi |
Middle name | |
Last name | Tagami |
Nippon Medical School Musashikosugi Hospital
Department of Emergency and Critical Care Medicine
211-8533
1-396 Kosugimachi, Nakahara-ku, Kawasaki, Kanagawa 211-8533, Japan
0447335181
https://nms-kosugi-eccm.com/covid19-joint-research/
t-tagami@nms.ac.jp
Nippon Medical School Musashikosugi Hospital
Self funding
Self funding
Nippon Medical School Musashikosugi Hospital
1-396 Kosugimachi, Nakahara-ku, Kawasaki, Kanagawa 211-8533, Japan
0447335181
t-tagami@nms.ac.jp
NO
2022 | Year | 03 | Month | 02 | Day |
Unpublished
4700
No longer recruiting
2020 | Year | 12 | Month | 07 | Day |
2020 | Year | 12 | Month | 07 | Day |
2021 | Year | 01 | Month | 01 | Day |
2022 | Year | 03 | Month | 31 | Day |
We planned to conduct an analysis based on the research proposal. Overall, 66 institutions from Japan announced their participation, and 102 research proposals were selected for the analyses. Research areas from the proposals included epidemiology, pathophysiology, therapeutic agents, ventilator settings, cost-benefit analyses, and prognosis prediction for COVID-19.
2022 | Year | 03 | Month | 02 | Day |
2022 | Year | 09 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053681